Phospho-Lck (Tyr505) (A3) rabbit mAb

www.abwizbio.com
Support: info@abwizbio.com
Order: sales@abwizbio.com

#2301

Store at: -20ºC

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry,WB	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

Format: Unconjugated

Cross Reactivity: Predicted to work with mouse, rat and other homologues.

Formulation: 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA

Preparation: Protein A+G

Reactivity: Human

Recommended Usage: 1µg/mL ? 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.

Immunogen: A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck

Description: Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLC?1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.

References:

Serafin V, Capuzzo G, Milani G, et al. (2017) Blood. 130: 2750-2761.
Lee KC, Ouwehand I, Giannini AL, et al. (2010) Leukemia. 24: 896-900.

9823 Pacific Heights Blvd., Suite J, San Diego, CA 92121



Western blot analysis of Jurkat cell extract untreated or treated with 200nM calyculin A for 30min using Phospho-Lck (Tyr505) antibody LckY505-A3 at 0.1 µg/mL. Cat. #2301.



	IgG	Treatment	Peptide Block	Median : BL1-A
	A3	IFN	Non-phos.	5166
	A3	Ctrl	Non-phos.	732
	A3	IFN	Phos.	1570
	A3	Ctrl	Phos.	601
	A3	IFN	-	7656
	A3	Ctrl	-	1104
	2° only	Ctrl	-	304

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFN? + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 µg/mL. Cat. #2301.



Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN? + IL-4 + pervanadate (green) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 µg/mL. Cat. #2301.



Western blot analysis of Jurkat cell extract, untreated or treated with calyculin A using 0.1 µg/mL Phospho-Lck (Tyr505) antibody LckY505-A3 Cat. #2301 or Company C antibody at 1 µg/mL (manufacturer?s recommended concentration) developed using the same exposure.

9823 Pacific Heights Blvd., Suite J, San Diego, CA 92121